It’s been a relatively dull start to the year for IPOs, with no well-known brand names hitting the markets. But some of the new stocks have posted big moves, especially in the biotech space: Ultragenyx (RARE) has doubled, and Dicerna Pharmaceuticals (DRNA) has gained more than 200%.
Here’s a list of the new stocks to watch for this week:
New Stocks to Watch – Amedica (NASDAQ:AMDA)
Amedica company uses silicon nitride technology to develop medical devices. Right now, it is marketing spinal fusion products. But the company has plans to introduce drugs for total hip and knee joint replacements. For the first nine months of last year, revenues came to $16.6 million and the net loss was $8.9 million. That compares to revenues of $17.1 million and a net loss of $10.7 million in the same period in 2012.
AMDA plans to issue 3.2 million shares at a range of $10 to $12, and the lead underwriter is JMP Securities.
New Stocks to Watch – Argos Therapeutics (NASDAQ:ARGS)
Argos Therapeutics is a clinical-stage biotech operator that is focused on personalized immunotherapies for the treatment of cancer and infectious diseases. The company’s lead candidate is AGS-003, which is targeted at metastatic renal cell carcinoma. The company is currently enrolling patients in a Phase 3 trial.
Another drug, AGS-004, is for HIV and is in Phase 2b clinical trials. The company has secured a $39.3 million grant from the National Institutes of Health for its development.
As for the IPO, ARGS plans to issue 4.3 million shares at a range of $13 to $15, and the lead underwriters include Piper Jaffray, Stifel and JMP Securities.
New Stocks to Watch – Auspex Pharmaceuticals (NASDAQ:ASPX)
This is a biotech firm that is focused on novel medicines for the treatment of orphan diseases (which affect fewer than 200,000 people in the US). The lead drug, SD-809, is in Phase 3 and is targeted at Huntington’s disease. The only other drug on the market is Tetrabenazine.
The company’s Chief Medical Officer is Dr. David Stamler, who led the approval of tetrabenazine for chorea associated with Huntington’s disease while at Prestwick Pharmaceuticals. What’s more, the Chief Development Officer, Dr. Samuel Saks, is the co-founder of Jazz Pharmaceuticals (JAZZ).
ASPX intends to sell 5.5 million shares at a range of $10 to $12, and the lead underwriters include Stifel and BMO Capital Markets.
New Stocks to Watch – Continental Building Products (NYSE:CBPX)
Continental Building Products, which actually planned to have its IPO last week, is a top manufacturer of gypsum wallboard and complementary finishing products. For the most part, it concentrates in the eastern part of the U.S. and Canada. Its brands include Lift Lite, Mold Defense and Weather Defense.
For the first nine months of last year, Continental Building Products revenues hit $287.9 million, up from $223.4 million the year prior. For this period, adjusted EBITDA also jumped from $26.5 million to $72.7 million.
CBPX intends to issue 13.2 million shares at a range of $16 to $18. The lead underwriters for the Continental Building Properties IPO include Citi (C), Credit Suisse (CS), Barclays (BCS), Deutsche Bank (DB) and RBC Capital Markets.
New Stocks to Watch – Egalet (NASDAQ:EGLT)
Egalet is a biotech operator that is focused on abuse-deterrent oral products for the treatment of pain. The lead candidate is Egalet-001 and it has just completed Phase 1 clinical trials.
Back in late 2013, the company signed a collaboration and license agreement with Shionogi Limited. The deal calls for an exclusive, royalty-bearing worldwide license to commercialize Egalet’s products. Shionogi made a $10 million upfront payment for the license.
EGLT plans to issue 3.5 million shares at a range of $11 to $13, and the lead underwriters include Stifel and JMP Securities.